Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06545331 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of XB010 in Subjects With Solid Tumors

StatusRecruiting
PhasePhase 1
SponsorExelixis
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 19 to 20v13
  2. Re-verified, no change to tracked fieldsv12
  3. Study sites: 17 to 19v11
  4. Study sites: 15 to 17v10
  5. Study sites: 12 to 15v9
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 11 to 12v8
  2. Study sites: 9 to 11v7
  3. Study sites: 8 to 9v6
  4. Enrollment target: 350 to 396 Study sites: 6 to 8 · Eligibility criteria shortened, about 5 wordsv5 Show 2 more changesShow less
    • Study sites: 6 to 8
    • Eligibility criteria shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 5 to 6v4
  6. Study sites: 4 to 5v3
  7. Study sites: 3 to 4v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exelixis
25 trials monitored
See 2 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
and 3 more diseases
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Trial Details
NCT Number NCT06545331
Lead Sponsor Exelixis
Conditions Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
Enrollment 396 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov